Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, ...

HUC1-394 is a peptide-based eye drop for dry eyes, licensed from NOVACELL Technology. According to the company, HUC1-394 ...

LENZ Therapeutics and Lotus Pharmaceutical announced Lotus has submitted a New Drug Application (NDA) to the Ministry of Food ...

Health Canada approved Eydenzelt, a biosimilar of Eylea, for multiple ophthalmic indications, based on comprehensive evidence including a phase 3 trial. The phase 3 trial demonstrated Eydenzelt's ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

Lid margin collarettes are common in moderate-to-severe DED, but most do not progress over time. No link was found between ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of ...

One of the most futuristic components of Hipsley’s work is the Virtual Eye Simulation Analyzer (VESA), an AI-enabled modeling ...

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

Aesthetic technologies are expanding ophthalmic practice into a broader sphere of patient care. AAO 2025 emphasized that ...